Dr. Robert Puchalski with SCENT Allergy & Sleep Medicine has completed the first procedure in the Midlands at Prisma Health Richland.
Inspire is an FDA-approved obstructive sleep apnea (OSA) treatment option for people who cannot use Continuous Positive Airway Pressure (CPAP) therapy.
OSA affects 22 million Americans. When left untreated, OSA can cause vehicle and workplace accidents, worsening mood and memory, stroke, heart attack, and even death. It occurs when the airway collapses during sleep and blocks the flow of oxygen to the brain. The brain senses a lack of oxygen and wakes the body up just long enough to take a breath, then falls back asleep. This cycle repeats throughout the night and causes poor, disruptive sleep.
Inspire works inside the body with a patient’s natural breathing process to treat sleep apnea. Mild stimulation opens the airway during sleep, allowing oxygen to flow naturally. The patient uses a small handheld remote to turn Inspire on before bed and off when they wake up.
The Inspire system is implanted during a short, outpatient procedure. The system is placed under the skin of the neck and chest through three small incisions. Most patients return home the same day and take over-the-counter pain medications to manage pain as needed.
The safety and efficacy of Inspire was evaluated during the STAR clinical trial. Five-year STAR trial outcomes show patients using Inspire experience significant reductions in sleep apnea events and significant improvements in quality of life measures. As of May 2020, there have been more than 100 peer-reviewed publications on Inspire. These publications show results consistent with those seen in the STAR trial.
“We are excited to have completed the first Inspire procedure at Prisma Health Richland Hospital.” said Dr. Puchalski, founding physician and Chairman at SCENT Allergy & Sleep Medicine. “Inspire represents a significant advancement in treating sleep apnea. It is clinically proven to reduce sleep apnea events, has a high level of patient satisfaction and a high therapy adherence.”